SHUKRAPHAR
Composite scorecard: 57/100 — Quality 98 · Valuation 0
| Share price | ₹51.93 |
| Year | Sales | Net profit | OPM |
|---|---|---|---|
| 2026 | ₹57 Cr | ₹22 Cr | 51.0% |
| 2025 | ₹33 Cr | ₹10 Cr | 39.0% |
Shukra Pharmaceuticals Limited manufactures and markets pharmaceutical products in India and internationally. Its product portfolio includes macrolides, quinolones, anti-bacterial, anti-fungal, anti-malarial, anti-viral, anti-protozoal, anti-anthelmintic, sedative and tranquillizer, anti-depressant, anti-manic, anti-emetic, anti-ulcer, beta blockers, diuretics, analgesic, muscle relaxants, anti-tuberculosis, vitamin products, anti-allergics, corticosteroids, hyper and hypoglycemic, and other products, as well as antibiotics, such as penicillin and cephalosporin. The company was formerly known